Picard Medical, Inc. (PMI) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Picard Medical, Inc. is a holding company that owns SynCardia Systems, LLC, which designs and manufactures the SynCardia Total Artificial Heart (TAH), an FDA-approved implantable system for patients with advanced heart failure. The company operates in a single segment and is classified as an emerging growth company and a smaller reporting company.
A pivotal event during this period was the completion of the Company's Initial Public Offering (IPO) on September 2, 2025, which significantly altered its capital structure and liquidity position.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
| Metric | Amount (in thousands) |
|---|---|
| Total Revenues | $3,931 |
| Net Loss | $(22,711) |
| Net Loss Per Share (Basic & Diluted) | $(0.96) |
| Cash and Cash Equivalents (Ending) | $2,813 |
| Total Assets | $13,521 |
| Total Liabilities | $5,553 |
| Stockholders' Equity | $7,968 |
| Operating Cash Flow | $(11,296) |
| Financing Cash Flow | $14,061 |
Note: The company reported a gross loss of $(615) for the nine-month period, indicating costs of revenue exceeded total revenues.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 11% ($376k) compared to the nine months ended September 30, 2024, driven primarily by a 10% increase in product sales in the United States.
- Net Loss Expansion: Net loss increased by 86% to $(22.7) million from $(12.2) million in the prior year period. This was primarily driven by a 498% increase in "Other expenses," specifically a $7.0 million derivative loss related to convertible notes and a 229% increase in interest expense due to debt discount amortization.
- Capital Structure Transformation:
- Debt Elimination: All outstanding convertible notes (2023 and 2024 series) and related party loans were converted to common stock or repaid in connection with the IPO. Convertible notes payable dropped from $14.8 million to $0.
- Equity Conversion: All 18.4 million shares of Series A-1 Preferred Stock were converted into approximately 39.6 million shares of common stock.
- Share Count: Outstanding common shares increased from 9.3 million (Dec 31, 2024) to 73.7 million (Sept 30, 2025) due to the IPO, conversions, and pre-IPO issuances.
- Liquidity: Cash and cash equivalents increased from $96k to $2.8 million, funded by $15.2 million in net proceeds from the IPO and other financing activities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management previously expressed substantial doubt about the company's ability to continue as a going concern due to operating losses and negative cash flows. However, the successful IPO in September 2025 raised sufficient capital to fund operations into 2025 based on the current business plan.
- Unusual Items: The financial results were significantly impacted by non-cash charges, including a $7.0 million derivative loss and $4.5 million in amortization of debt discounts, which were extinguished upon the conversion of debt to equity during the IPO.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses including a lack of segregation of duties, lack of formal review processes, and insufficient controls over related party transactions. A remediation plan is underway.
- Risk Factors: Key risks include the need for additional financing to achieve profitability, dependence on a limited number of customers (Customer A accounted for 49% of revenue), and the challenges of scaling operations as a public company.
Investor Verification Checklist
- Post-IPO Liquidity Runway: Verify the specific duration of the $2.8 million cash balance relative to the company's burn rate and future capital requirements.
- Customer Concentration: Assess the risk associated with Customer A representing nearly 50% of revenue and Customer E (Serbia) representing 12%.
- Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in internal controls, particularly regarding related party transactions and segregation of duties.
- Revenue vs. Cost Structure: Analyze the path to gross profitability, as the company currently operates with a gross loss (Cost of Revenue > Revenue).
- China Joint Venture: Review the status of the contingent investment in SynCardia Medical (Beijing), Inc., which remains pending based on market conditions.